Market cap of Medtronic plc [MDT] reaches 117.87B – now what?


Medtronic plc [NYSE: MDT] stock went on a downward path that fall over -0.29% on Tuesday, amounting to a one-week price decrease of less than -1.99%. The company report on July 12, 2022 that Medtronic announces co-promotion agreement with CathWorks, with path toward acquisition.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Partnership underscores Medtronic’s commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment.

CathWorks’ FFRangio® System provides diagnostic and physiologic information through artificial intelligence to potentially disrupt traditional FFR and revolutionize the management of coronary artery disease.

Over the last 12 months, MDT stock dropped by -30.82%. The one-year Medtronic plc stock forecast points to a potential upside of 22.98. The average equity rating for MDT stock is currently 2.10, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $117.87 billion, with 1.34 billion shares outstanding and 1.33 billion shares in the current float. Compared to the average trading volume of 5.88M shares, MDT stock reached a trading volume of 6190520 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Medtronic plc [MDT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MDT shares is $115.15 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MDT stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for Medtronic plc shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on July 06, 2022. While these analysts kept the previous recommendation, Atlantic Equities dropped their target price from $125 to $105. The new note on the price target was released on June 01, 2022, representing the official price target for Medtronic plc stock. On April 13, 2022, analysts decreased their price target for MDT shares from 124 to 121.

The Average True Range (ATR) for Medtronic plc is set at 1.96, with the Price to Sales ratio for MDT stock in the period of the last 12 months amounting to 3.72. The Price to Book ratio for the last quarter was 2.26, with the Price to Cash per share for the same quarter was set at 7.96. Price to Free Cash Flow for MDT in the course of the last twelve months was 45.40 with Quick ratio for the last quarter at 1.50.

MDT Stock Performance Analysis:

Medtronic plc [MDT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.99. With this latest performance, MDT shares dropped by -4.84% in over the last four-week period, additionally sinking by -15.66% over the last 6 months – not to mention a drop of -30.82% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MDT stock in for the last two-week period is set at 36.76, with the RSI for the last a single of trading hit 36.68, and the three-weeks RSI is set at 37.15 for Medtronic plc [MDT]. The present Moving Average for the last 50 days of trading for this stock 96.32, while it was recorded at 89.25 for the last single week of trading, and 107.54 for the last 200 days.

Insight into Medtronic plc Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Medtronic plc [MDT] shares currently have an operating margin of +22.48 and a Gross Margin at +63.13. Medtronic plc’s Net Margin is presently recorded at +15.91.

Return on Equity for this stock inclined to 9.69, with Return on Assets sitting at 5.48.

Medtronic plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.90.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MDT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Medtronic plc go to 12.66%.

Medtronic plc [MDT] Insider Position Details

There are presently around $96,135 million, or 84.10% of MDT stock, in the hands of institutional investors. The top three institutional holders of MDT stocks are: VANGUARD GROUP INC with ownership of 120,557,488, which is approximately 6.543% of the company’s market cap and around 0.24% of the total institutional ownership; BLACKROCK INC., holding 107,991,652 shares of the stock with an approximate value of $9.61 billion in MDT stocks shares; and STATE STREET CORP, currently with $5.2 billion in MDT stock with ownership of nearly 0.914% of the company’s market capitalization.

Positions in Medtronic plc stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 1,184 institutional holders increased their position in Medtronic plc [NYSE:MDT] by around 67,974,922 shares. Additionally, 819 investors decreased positions by around 68,337,332 shares, while 222 investors held positions by with 944,466,273 shares. The mentioned changes placed institutional holdings at 1,080,778,527 shares, according to the latest SEC report filing. MDT stock had 194 new institutional investments in for a total of 12,093,192 shares, while 134 institutional investors sold positions of 11,346,432 shares during the same period.